



3rd Symposium for Emerging Viral Diseases

Campus Biotech, Geneva, Switzerland, 7-9 December

2022 <https://www.unige.ch/emerging-virus-symposium/>

Maria Eugenia Zaballa :

“Seroprevalence of anti-SARS-CoV 2 antibodies in Geneva: a tale of two years”



Main affiliation:

Geneva University Hospitals, Switzerland

Actual Position:

Scientific collaborator & Project manager

Website:

<https://www.hug.ch/medecine-premier-recours/uep>

<https://www.specchio-covid19.ch/>

María Eugenia Zaballa obtained her Master in Biotechnology and her PhD in Chemical Biology from the University of Rosario, Argentina. She then moved to Switzerland, where she trained in the field of Cell Biology as a HFSP and SystemsX.ch postdoctoral fellow at the Swiss Federal Institute of Technology Lausanne (EPFL). In April 2020, she joined the Population Epidemiology Unit of the Primary Care Division at the Geneva University Hospitals (HUG) and has been working since then as a scientific collaborator and project manager on population-based COVID-19 studies.